Bellevue Life Sciences Acquisition in a proxy filing asks shareholders to vote for a six-month extension that would give the SPAC until Nov. 14 to complete a deal.
The SPAC in November announced a merger agreement with OSR Holdings Co., Ltd., a global healthcare holding company.
Bellevue in July had signed an exclusive, non-binding letter of intent with OSR. Peter Kuk Hyoun Hwang is CEO of both companies.
The SPAC lost about 38% of its trust to redemptions on an extension vote late last year. The SPAC had raised $69 million in a February IPO.
Bellevue would own at least 60% of the new OSR outstanding shares, with the right to acquire the remainder.
The merged company would be named OSR Biosciences and its common stock and warrants would list on the Nasdaq, if the deal is approved. Read more.
